Sign Up Today and Learn More About SOMAĆ Pharmaceuticals Stock
Invest in or calculate the value of your shares in SOMAĆ Pharmaceuticals or other pre-IPO companies through EquityZen's platform.
SOMAĆ Pharmaceuticals Stock (SOPH)
SOMAĆ Pharmaceuticals is a pharmaceutical and biotech company that specializes in cannabinoid-containing pharmaceutical medicines.
About SOMAĆ Pharmaceuticals Stock
Founded
2019
Industries
Community and Lifestyle, Science and Engineering, Health Care
SOMAĆ Pharmaceuticals Press Mentions
Stay in the know about the latest news on SOMAĆ Pharmaceuticals
Please wait while your request is being verified...
businessofcannabis ā¢ May 26, 2025
āPortugal estĆ” a estabelecer-se como um centro de cultivo e produĆ§Ć£o de canĆ”bis medicinal na Europaā ā Michael Sassano, SOMAĆ Pharmaceuticals
pmemagazine ā¢ May 26, 2025
Thailand: The Cannabis Capital of Asia and Beyond
bevinfogroup ā¢ May 15, 2025
Herer Legacy Goes Global: Dan Herer and Somai Pharmaceuticals Bring the Jack Herer Standard to the World
honeysucklemag ā¢ May 06, 2025
How To Trade Cannabis Flower Globally: A Story Of Capital
talkmarkets ā¢ May 06, 2025
SOMAĆ Pharmaceuticals Management
Leadership team at SOMAĆ Pharmaceuticals
Chief Operating Officer and Co-Founder
George Bellow
Founder, Chairman and CEO
Michael Sassano
Join now and verify your accreditation status to gain access to:
- SOMAĆ Pharmaceuticals Current Valuation
- SOMAĆ Pharmaceuticals Stock Price
- SOMAĆ Pharmaceuticals Management
- Available deals in SOMAĆ Pharmaceuticals and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- SOMAĆ Pharmaceuticals Cap Table and Funding History by Share Class and Liquidity Preferences
- SOMAĆ Pharmaceuticals Revenue and Financials
- SOMAĆ Pharmaceuticals Highlights
- SOMAĆ Pharmaceuticals Business Model
- SOMAĆ Pharmaceuticals Risk Factors
- SOMAĆ Pharmaceuticals Research Report from SACRA Research
Trading SOMAĆ Pharmaceuticals Stock
How to invest in SOMAĆ Pharmaceuticals stock?
Accredited investors can buy pre-IPO stock in companies like SOMAĆ Pharmaceuticals through EquityZen funds. These investments are made available by existing SOMAĆ Pharmaceuticals shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event ā house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell SOMAĆ Pharmaceuticals stock?
Shareholders can sell their SOMAĆ Pharmaceuticals stock through EquityZen's private company marketplace. EquityZen's network includes over 370K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
